Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Neuroendocrine small cell carcinoma of the uterine cervix: What disease? What treatment? Report of ten cases and a review of the literature
Autore:
Delaloge, S; Pautier, P; Kerbrat, P; Castaigne, D; Haie-Meder, C; Duvillard, P; Guivarch, C; Goupil, A; Borel, C; Lhomme, C;
Indirizzi:
Inst Gustave Roussy, Dept Med, F-94800 Villejuif, France Inst Gustave Roussy Villejuif France F-94800 , F-94800 Villejuif, France Ctr Eugene Marquis, Rennes, France Ctr Eugene Marquis Rennes FranceCtr Eugene Marquis, Rennes, France Clin Pasteur, Brest, France Clin Pasteur Brest FranceClin Pasteur, Brest, France Ctr Rene Huguenin, St Cloud, France Ctr Rene Huguenin St Cloud FranceCtr Rene Huguenin, St Cloud, France Ctr Paul Strauss, Strasbourg, France Ctr Paul Strauss Strasbourg FranceCtr Paul Strauss, Strasbourg, France
Titolo Testata:
CLINICAL ONCOLOGY
fascicolo: 6, volume: 12, anno: 2000,
pagine: 357 - 362
SICI:
0936-6555(2000)12:6<357:NSCCOT>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
GYNECOLOGIC-ONCOLOGY-GROUP; ENDOCRINE TUMORS; HUMAN-PAPILLOMAVIRUS; LYMPH-NODES; CISPLATIN; THERAPY; CANCER; CHEMOTHERAPY; ETOPOSIDE; PACLITAXEL;
Keywords:
chemotherapy; neuroendocrine; small cell carcinoma; uterine cervix;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Delaloge, S Inst Gustave Roussy, Dept Med, 39 Rue Camille Desmoulins, F-94800 Villejuif, France Inst Gustave Roussy 39 Rue Camille Desmoulins Villejuif France F-94800
Citazione:
S. Delaloge et al., "Neuroendocrine small cell carcinoma of the uterine cervix: What disease? What treatment? Report of ten cases and a review of the literature", CL ONCOL-UK, 12(6), 2000, pp. 357-362

Abstract

Neuroendocrine small cell carcinoma of the uterine cervix (NESCCC) is an entity with very aggressive behaviour. The optimal initial therapeutic approach to this rare disease has not yet been clearly defined. We reviewed our experience of this disease over the past 10 years with regard to chemosensitivity. Since 1988, ten patients (mean age 33 years; range24-47) have been diagnosed with NESCCC and treated in our institutions. Disease stage at presentation was IA (one), IB (five, two with lymph node involvement), IIB (one), IIIB (one), and IV (two). One patient had metastatic disease at presentation; three developed metastases during initial treatment. Eight patients underwent surgery and eight received radiation therapy. Six patients received pre- or postoperative cisplatinumvepeside (PE) combination chemotherapy, either alone or concurrently with radiation therapy. PE alone as primary chemotherapy led to disease stabilization in the two patients so treated; concurrent PE and radiation therapy resulted in a pathological complete response in one patient. Eight patients relapsed within 16 months and died of their disease within 29 months: from the initial diagnosis. Two patients are alive with no evidence of disease at 13 and 53 months. Our series confirms the previously described very poor prognosis of NESCCC, despite initial aggressive multidisciplinary treatment. It may be that the introduction of chemotherapy, especially combined primary chemoradiotherapy, might allow patients to do a little better, although at the moment there is no good evidence one way or the other.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 14:23:28